Arcus Biosciences, Summit Therapeutics team up to test casdatifan-ivonescimab combo in kidney cancer

Reuters2026/07/22 20:40

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Summit entered a clinical trial collaboration with Arcus to test ivonescimab with Arcus’s casdatifan in clear cell renal cell carcinoma.
The combination will be added as a new cohort in Arcus’s ARC-20 metastatic kidney cancer platform study.
Summit will supply ivonescimab; Arcus will sponsor and run the study; both companies will share costs.
Each party keeps development and commercial rights to its own drug; initial data is expected by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722789939) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arcus Biosciences, Summit Therapeutics team up to test casdatifan-ivonescimab combo in kidney cancer

You may also like

Crypto prices